Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Renal pelvis and ureter cancer
Trial Status:  Active
Results 1-25 of 83 for your search:
Start Over
Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: RRK4368, 2012-002552-16, NCT01668459
Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Secavin-12, NCT01830231
Tranexamic Acid During Cystectomy Trial (TACT) Pilot Study
Phase: Phase III, Phase II
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CIHR MOP-123361, Control # 162042, NCT01869413
A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13 URO 02, NCT02240017
Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients
Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492
A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICR-CTSU/2011/10031, 2011-002577-33, ISRCTN98387754, CRUK/11/027, 11/NW/0782, NCT01993979
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-045, 2014-002009-40, NCT02256436
A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO29294, 2014-003231-19, NCT02302807
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15679, I4T-MC-JVDC, 2014-003655-66, NCT02426125
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00170, CDR0000492014, PHII-75, 7435, N01CM00038, N01CM00071, N01CM62201, N01CM62209, P30CA033572, U01CA062505, CCC-PHII-75, NCI-7435, NCT00365157
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CA-ALT-801-01-10, NCT01326871
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INCB 24360-202, NCT02178722
Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: HCRN GU14-188, NCT02365766
Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: pelvis ureter Neoplasms-IRE-01, NCT02430779
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ABX207-GU07CA, NCT00683059
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0933, NCI-2012-01675, NCT00756639
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BLDR0010, SU-04152010-5683, NCT01108055
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000684016, WCTU-TOUCAN, ISRCTN-68146831, EUDRACT-2009-010140-33, EU-21066, CRUK-09/024, WCTU-SPON-672-09, ZENECA-WCTU-TOUCAN, NCT01191892
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HCRN GU10-147, NCT01215136
Tesetaxel for Previously Treated Patients With Bladder Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TOBL204, NCT01215877
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-208, NCT01261728
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-071, NCT01589094
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: INT01/12, 2011-005983-12, NCT01620970
Start Over